Engineered AAV Capsids for Muscle-Specific Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional recombinant adeno-associated viruses (rAAVs) have limited cell tropism, requiring high doses for effective delivery to non-liver tissues like nervous and cardiac muscles, leading to liver toxicity and manufacturing challenges, with species-specific transduction efficiency variations complicating preclinical studies.
Innovation Solution
Engineered AAV vectors with n-mer motifs, such as XmRGDXn, targeting muscle cells, enhance muscle-specific tropism and reduce immunogenicity, allowing for efficient delivery of therapeutic cargos like mini-dystrophin genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional rAAVs with natural capsid variants are used for delivery to non-liver tissues, then the virus can infect the liver efficiently, but the transduction efficiency in other cell types and tissues is limited and liver toxicity occurs due to high doses required
Solution Approach 1:
The patent applies local quality by engineering specific regions of the AAV capsid protein with targeted n-mer motifs (such as XmRGDXn sequences) to confer muscle-specific binding properties. This localized modification of the capsid structure enables selective recognition and binding to muscle cell surface receptors, while leaving other regions of the virus intact for general viral functions. The targeted modification at specific capsid locations achieves tissue-specific delivery without affecting overall viral structure or requiring high doses that cause liver toxicity.
2Reliability
If large doses of conventional rAAV are administered to achieve effective transduction in non-liver tissues, then transduction efficiency improves, but manufacturing challenges arise and liver toxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the physical-chemical properties of the AAV capsid through insertion of n-mer motifs with specific amino acid sequences. These sequence changes alter the capsid's surface properties, binding affinity, and tissue tropism parameters. By changing the capsid sequence parameters (specifically incorporating motifs like XmRGDXn where X represents variable amino acids), the virus achieves higher transduction efficiency at lower doses, making manufacturing feasible and reducing the burden of producing large quantities of virus for clinical use.
3Productivity
If preclinical studies are conducted in mouse models using conventional rAAVs, then research can be performed, but the results do not accurately reflect human responses due to species-specific differences in viral capsid recognition
Solution Approach 1:
The patent applies universality by designing AAV capsid variants with n-mer motifs that recognize conserved cellular receptors across species boundaries. The engineered capsids (such as AAV9 variants with inserted motifs) possess multi-functional binding capabilities that enable them to infect both mouse and human cells with similar efficiency. This cross-species recognition capability allows preclinical studies in mouse models to produce results that accurately predict human responses, bridging the gap between animal research and clinical application.
Data Source
AI summary
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.